VALLEY FORGE, Pa.--(BUSINESS WIRE)--Aug. 10, 2017--
The Board of Directors of AmerisourceBergen Corporation (NYSE: ABC)
today declared a quarterly dividend of $0.365 per common share, payable
September 5, 2017, to stockholders of record at the close of business on
August 21, 2017.
About AmerisourceBergen
AmerisourceBergen provides pharmaceutical products, value-driving
services and business solutions that improve access to care. Tens of
thousands of healthcare providers, veterinary practices and livestock
producers trust us as their partner in the pharmaceutical supply chain.
Global manufacturers depend on us for services that drive commercial
success for their products. Through our daily work—and powered by our
20,000 associates—we are united in our responsibility to create
healthier futures. AmerisourceBergen is ranked #11 on the Fortune 500,
with more than $145 billion in annual revenue. The company is
headquartered in Valley Forge, Pa. and has a presence in 50+ countries.
Learn more at amerisourcebergen.com.
AmerisourceBergen's Cautionary Note Regarding Forward-Looking
Statements
Certain of the statements contained in this release are "forward-looking
statements" within the meaning of Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934. Words such
as "expect," "likely," "outlook," "forecast," "would," "could,"
"should," "can," "will," "project," "intend," "plan," "continue,"
"sustain," "synergy," "on track," "believe," "seek," "estimate,"
"anticipate," "may," "possible," "assume," variations of such words, and
similar expressions are intended to identify such forward-looking
statements. These statements are based on management's current
expectations and are subject to uncertainty and change in circumstances.
These statements are not guarantees of future performance and are based
on assumptions that could prove incorrect or could cause actual results
to vary materially from those indicated. Among the factors that could
cause actual results to differ materially from those projected,
anticipated, or implied are the following: unfavorable trends in brand
and generic pharmaceutical pricing, including in rate or frequency of
price inflation or deflation; competition and industry consolidation of
both customers and suppliers resulting in increasing pressure to reduce
prices for our products and services; changes in pharmaceutical market
growth rates; substantial defaults in payment, material reduction in
purchases by or the loss, bankruptcy or insolvency of a major customer;
changes to the customer or supplier mix; the retention of key customer
or supplier relationships under less favorable economics or the adverse
resolution of any contract or other dispute with customers or suppliers;
changes to customer or supplier payment terms; the disruption of the
Company's cash flow and ability to return value to its stockholders in
accordance with its past practices; risks associated with the strategic,
long-term relationship between Walgreens Boots Alliance, Inc. and the
Company, including with respect to the pharmaceutical distribution
agreement and/or the global sourcing arrangement; changes in the United
States healthcare and regulatory environment, including changes that
could impact prescription drug reimbursement under Medicare and
Medicaid; increasing governmental regulations regarding the
pharmaceutical supply channel and pharmaceutical compounding; federal
and state government enforcement initiatives to detect and prevent
suspicious orders of controlled substances and the diversion of
controlled substances; prosecution or suit by federal, state and other
governmental entities of alleged violations of laws and regulations
regarding controlled substances, and any related disputes, including
shareholder derivative lawsuits; increased federal scrutiny and
litigation, including qui tam litigation, for alleged violations of laws
and regulations governing the marketing, sale, purchase and/or
dispensing of pharmaceutical products or services, and associated
reserves and costs, including the litigation reserves recorded in
connection with agreements in principle reached with the USAO-EDNY and
the USAO-SDNY; material adverse resolution of pending legal proceedings;
declining reimbursement rates for pharmaceuticals; the acquisition of
businesses that do not perform as expected, or that are difficult to
integrate or control, including the integration of PharMEDium, or the
inability to capture all of the anticipated synergies related thereto;
regulatory action in connection with the production, labeling or
packaging of products compounded by our compounded sterile preparations
(CSP) business; declining economic conditions in the United States and
abroad; financial market volatility and disruption; the loss, bankruptcy
or insolvency of a major supplier; interest rate and foreign currency
exchange rate fluctuations; managing foreign expansion, including
non-compliance with the U.S. Foreign Corrupt Practices Act, anti-bribery
laws and economic sanctions and import laws and regulations;
malfunction, failure or breach of sophisticated information systems to
operate as designed; risks generally associated with data privacy
regulation and the international transfer of personal data; changes in
tax laws or legislative initiatives that could adversely affect the
Company's tax positions and/or the Company's tax liabilities or adverse
resolution of challenges to the Company's tax positions; natural
disasters or other unexpected events that affect the Company’s
operations; the impairment of goodwill or other intangible assets,
resulting in a charge to earnings; and other economic, business,
competitive, legal, tax, regulatory and/or operational factors affecting
the Company's business generally. Certain additional factors that
management believes could cause actual outcomes and results to differ
materially from those described in forward-looking statements are set
forth (i) in Item 1A (Risk Factors) in the Company’s Annual Report on
Form 10-K for the fiscal year ended September 30, 2016 and elsewhere in
that report and (ii) in other reports filed by the Company pursuant to
the Securities Exchange Act.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170810005666/en/
Source: AmerisourceBergen Corporation
AmerisourceBergen Corporation
Keri P. Mattox
Vice
President, Corporate & Investor Relations
610-576-7801
kmattox@amerisourcebergen.com
or
Bennett
S. Murphy
Director, Corporate & Investor Relations
610-727-3693
bmurphy@amerisourcebergen.com